Am J Clin Oncol: The therapeutic effect of new assisted chemotherapy in patients with removable and marginal removable pancreatic cancer.

Pancreatic catheter adenocarcinoma is an incurable cancer, and surgical excision remains the only potential option for its treatment.
, however, only about 10 to 20 percent of patients who can be surgically removed survive long-term.
results show that new complementary therapy can be used for hidden microstastable lesions.
this study aims to report on our organization's experience with new complementary chemical radiotherapy (CRT) programmes in excision and edge removable pancreatic cancer.
patients undergo two cycles of induced chemotherapy with FOLFOX and then receive CRT and gemitabine and intensity modulation radiotherapy (IMRT).
included 24 patients from April 2014 to June 2017.
18 patients were removable at the edge and 6 were removable.
all patients received FOLFOX induced chemotherapy.
13 patients had a pancreatic excision after CRT, with a removal rate of 62%.
11 patients achieved R0 excision (84.6%) and 2 patients achieved R1 excision (15.4%).
For patients receiving excision, the medium progression-free survival (PFS) was 31 months, the 1-year PFS rate was 69.2% (95% confidence interval ,0.48-0.99), and the two-year PFS rate was 51.9% (95% CI, 0.3-0.89).
medium total survival (OS) was 34.8 months (95% CI, 1.045 to infinity), 91.7% (95% CI, 0.77 to 1.0), and 75% (95% CI, 0.54 to 1.0) in 2 years.
patients who underwent surgery had a median CA of CA 19-9 (range, 18 to 2154) at the time of screening, which dropped to 146.9 (range, 18 to 462) after the CRT before removal.
the results showed that the new complementary treatment of CRT for marginally excisable and excisable pancreatic catheter adenocarcinoma promoted R0 excision in 84% of patients undergoing surgery.
.